Our lab previously demonstrated that the inhibition of oncogenic BRAF results in dramatic tumor reduction in a model of human ATC and several other groups have shown that dasatinib treatment effectively reduces tumor growth in mice implanted with human BRAFV600E-positive thyroid cancer cells [6, 8, 23, 31]. The gene discussed is BRAF; the disease is neoplasm.